ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)
ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)
Breast Cancer
DRUG: ABX, cisplatin|DRUG: Gemcitabine, Cisplatin
PFS (Progression Free Survival), 6 weeks
Objective Response Rate (ORR), 6 weeks|Number of Participants with Adverse Events as a Measure of Safety and Tolerability, 6 weeks|Overall Survival (OS), From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
A Phase III, Multicenter, Randomized Study of ABX Plus Cisplatin (AP) Versus Gemcitabine Plus Cisplatin (GP) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer